AcelRx Pharmaceuticals, Inc. (ACRX)
(Delayed Data from NSDQ)
$3.66 USD
+0.10 (2.81%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMEarnings News For ACRX
-
AcelRx Pharmaceuticals: Q3 Earnings Snapshot
-
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates
-
AcelRx Pharmaceuticals: Q2 Earnings Snapshot
-
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
-
AcelRx Pharmaceuticals: Q1 Earnings Snapshot
-
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
-
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
-
AcelRx Pharmaceuticals: Q4 Earnings Snapshot
-
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update
-
AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates
-
AcelRx Pharmaceuticals: Q3 Earnings Snapshot
-
AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates
-
AcelRx Pharmaceuticals: Q2 Earnings Snapshot
-
AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates
-
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates
-
AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
-
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates
-
Will AcelRx Pharmaceuticals (ACRX) Report Negative Q2 Earnings? What You Should Know
-
AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
-
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates